Humacyte Inc Market Cap ($97.80 Million)
Market Cap & Net Worth: Humacyte Inc (HUMA)
Humacyte Inc market cap. Humacyte Inc (NASDAQ:HUMA) has a market capitalization of $97.80 Million ($97.80 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #19081 globally and #4413 in its home market, demonstrating a 9.96% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Humacyte Inc's stock price $0.44 by its total outstanding shares 222019108 (222.02 Million). Also see HUMA cash generation efficiency for how efficiently the company converts equity into cash flow.
Humacyte Inc Market Cap History (2020–2026)
Humacyte Inc market cap history from 2020 to 2026. Data shows change from $2.26 Billion to $97.80 Million (-40.62% CAGR). Check Humacyte Inc share price for real-time trading data and today's change.
Index Memberships
Humacyte Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #529 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #1825 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.83 Trillion | 0.01% | #237 of 263 |
Weight: Humacyte Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Humacyte Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Humacyte Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore HUMA net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
104.64x
Humacyte Inc's market cap is 104.64 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $2.26 Billion | $1.49 Million | -$66.52 Million | 1514.38x | N/A |
| 2021 | $1.61 Billion | $1.26 Million | -$26.48 Million | 1274.46x | N/A |
| 2022 | $468.46 Million | $1.56 Million | -$11.96 Million | 299.34x | N/A |
| 2025 | $213.25 Million | $2.04 Million | -$40.83 Million | 104.64x | N/A |
Competitor Companies of HUMA by Market Capitalization
Companies near Humacyte Inc in the global market cap rankings as of November 5, 2026. Also see Humacyte Inc assets under control for a full breakdown of the balance sheet.
Key companies related to Humacyte Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Humacyte Inc (2020–2026)
Market capitalization of Humacyte Inc from 2020 to today. Between 2020 and today, Humacyte Inc's market cap moved from $2.26 Billion to $ 97.80 Million, with a yearly change of -40.62%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $97.80 Million | -54.14% |
| 2025 | $213.25 Million | -80.98% |
| 2024 | $1.12 Billion | +77.82% |
| 2023 | $630.53 Million | +34.60% |
| 2022 | $468.46 Million | -70.90% |
| 2021 | $1.61 Billion | -28.71% |
| 2020 | $2.26 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Humacyte Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $97.80 Million USD |
| MoneyControl | $97.80 Million USD |
| MarketWatch | $97.80 Million USD |
| marketcap.company | $97.80 Million USD |
| Reuters | $97.80 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Humacyte Inc
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to b… Read more